Pharmaceuticals
Acadia Pharmaceuticals is a biopharmaceutical company committed to developing innovative treatments for underserved neurological and rare disease communities. The company's commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome, representing significant advances in these therapeutic areas. Acadia is advancing a robust pipeline with mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, alongside earlier-stage programs addressing other underserved patient needs. The company focuses on turning scientific promise into meaningful innovation that makes a tangible difference for patients with serious neurological conditions.
Beta · Sourced from candidate reports
Be the first to share your experience with Acadia Pharmaceuticals Inc..
Your reply helps other candidates know what to expect.
